Population Pharmacokinetics of Lopinavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected South African Children

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2010 Jun 17

PMID 20552180

Citations 14

Authors

Doaa Elsherbiny

Yuan Ren

Helen McIlleron

Gary Maartens

Ulrika S H Simonsson

Affiliations

Soon will be listed here.

Abstract

Purpose: The population pharmacokinetics (PK) of lopinavir in tuberculosis (TB)/human immunodeficiency virus (HIV) co-infected South African children taking super-boosted lopinavir (lopinavir/ritonavir ratio 1:1) as part of antiretroviral treatment in the presence of rifampicin were compared with the population PK of lopinavir in HIV-infected South African children taking standard doses of lopinavir/ritonavir (ratio 4:1).

Methods: Lopinavir concentrations were measured in 15 TB/HIV-co-infected paediatric patients who were sampled during and after rifampicin-based TB treatment and in 15 HIV-infected children without TB. During TB therapy, the dose of ritonavir was increased to lopinavir/ritonavir 1:1 in order to compensate for the induction of rifampicin. The children received median (interquartile range=IQR) doses of lopinavir 292 mg/m(2) (274, 309) and ritonavir 301 mg/m(2) (286, 309) twice daily. After TB treatment completion the children received standard doses of lopinavir/ritonavir 4:1 (median [IQR] lopinavir dose 289 mg/m(2) [286, 303] twice daily) as did those without TB (median [IQR] lopinavir dose 265 mg/m(2) [249, 289] twice daily).

Results: Lopinavir oral clearance (CL/F) was about 30% lower in children without TB than in co-infected children treated with super-boosted lopinavir. However, the predicted lopinavir C(min) was above the recommended minimum therapeutic concentration during TB/HIV co-treatment in the 15 children. Lopinavir CL/F increased linearly during the dosing interval.

Conclusions: Increasing the ritonavir dose to achieve a lopinavir/ritonavir ratio of 1:1 when given in combination with rifampicin-based TB treatment did not completely compensate for the enhancement of lopinavir CL/F caused by rifampicin. The time-dependent lopinavir CL/F might be due to a time-dependent recovery from ritonavir inhibition of lopinavir metabolism during the dosing interval.

Citing Articles

A fully automatic tool for development of population pharmacokinetic models.

Chen X, Nordgren R, Belin S, Hamdan A, Wang S, Yang T CPT Pharmacometrics Syst Pharmacol. 2024; 13(10):1784-1797.

PMID: 39190006 PMC: 11494844. DOI: 10.1002/psp4.13222.

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.

Jacobs T, Svensson E, Musiime V, Rojo P, Dooley K, McIlleron H J Antimicrob Chemother. 2020; 75(12):3433-3457.

PMID: 32785712 PMC: 7662174. DOI: 10.1093/jac/dkaa328.

Model-Based Residual Post-Processing for Residual Model Identification.

Ibrahim M, Nordgren R, Kjellsson M, Karlsson M AAPS J. 2018; 20(5):81.

PMID: 29968184 DOI: 10.1208/s12248-018-0240-7.

Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes.

Archary M, Mcllleron H, Bobat R, La Russa P, Sibaya T, Wiesner L Pediatr Infect Dis J. 2017; 37(4):349-355.

PMID: 29227461 PMC: 5849509. DOI: 10.1097/INF.0000000000001867.

Pharmacokinetics and Drug-Drug Interactions of Lopinavir-Ritonavir Administered with First- and Second-Line Antituberculosis Drugs in HIV-Infected Children Treated for Multidrug-Resistant Tuberculosis.

van der Laan L, Garcia-Prats A, Schaaf H, Tikiso T, Wiesner L, de Kock M Antimicrob Agents Chemother. 2017; 62(2).

PMID: 29133558 PMC: 5786799. DOI: 10.1128/AAC.00420-17.

References

Paton N, Ng Y . Body composition studies in patients with wasting associated with tuberculosis. Nutrition. 2006; 22(3):245-51. DOI: 10.1016/j.nut.2005.06.009. View

King J, Kimberlin D, Aldrovandi G, Acosta E . Antiretroviral pharmacokinetics in the paediatric population: a review. Clin Pharmacokinet. 2002; 41(14):1115-33. DOI: 10.2165/00003088-200241140-00001. View

Ren Y, Nuttall J, Egbers C, Eley B, Meyers T, Smith P . Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr. 2008; 47(5):566-9. DOI: 10.1097/QAI.0b013e3181642257. View

Culm-Merdek K, von Moltke L, Gan L, Horan K, Reynolds R, Harmatz J . Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir. Clin Pharmacol Ther. 2006; 79(3):243-54. DOI: 10.1016/j.clpt.2005.11.009. View

Sun J, He Z, Cheng G, Wang S, Hao X, Zou M . Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit. 2004; 10(1):RA5-14. View

Niemi M, Backman J, Fromm M, Neuvonen P, Kivisto K . Pharmacokinetic interactions with rifampicin : clinical relevance. Clin Pharmacokinet. 2003; 42(9):819-50. DOI: 10.2165/00003088-200342090-00003. View

Venkatakrishnan K, Obach R, Rostami-Hodjegan A . Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment. Xenobiotica. 2007; 37(10-11):1225-56. DOI: 10.1080/00498250701670945. View

Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M . CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos. 2002; 30(7):795-804. DOI: 10.1124/dmd.30.7.795. View

Rae J, Johnson M, Lippman M, Flockhart D . Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther. 2001; 299(3):849-57. View

10.

la Porte C, Colbers E, Bertz R, Voncken D, Wikstrom K, Boeree M . Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers. Antimicrob Agents Chemother. 2004; 48(5):1553-60. PMC: 400571. DOI: 10.1128/AAC.48.5.1553-1560.2004. View

11.

Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely M . Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2009; 53(6):2532-8. PMC: 2687254. DOI: 10.1128/AAC.01374-08. View

12.

Ette E . Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997; 37(6):486-95. DOI: 10.1002/j.1552-4604.1997.tb04326.x. View

13.

Chadwick E, Capparelli E, Yogev R, Pinto J, Robbins B, Rodman J . Pharmacokinetics, safety and efficacy of lopinavir/ritonavir in infants less than 6 months of age: 24 week results. AIDS. 2007; 22(2):249-55. DOI: 10.1097/QAD.0b013e3282f2be1d. View

14.

Kappelhoff B, Huitema A, Crommentuyn K, Mulder J, Meenhorst P, van Gorp E . Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. Br J Clin Pharmacol. 2005; 59(2):174-82. PMC: 1884743. DOI: 10.1111/j.1365-2125.2004.02241.x. View

15.

Paton N, Ng Y, Chee C, Persaud C, Jackson A . Effects of tuberculosis and HIV infection on whole-body protein metabolism during feeding, measured by the [15N]glycine method. Am J Clin Nutr. 2003; 78(2):319-25. DOI: 10.1093/ajcn/78.2.319. View

16.

Lawn S, Bekker L, Middelkoop K, Myer L, Wood R . Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis. 2006; 42(7):1040-7. DOI: 10.1086/501018. View

17.

Verweel G, Burger D, Sheehan N, Bergshoeff A, Warris A, van der Knaap L . Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below. Antivir Ther. 2007; 12(4):453-8. View

18.

Jeena P, Pillay P, Pillay T, Coovadia H . Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis. 2002; 6(8):672-8. View

19.

Ouellet D, Hsu A, Qian J, Locke C, Eason C, CAVANAUGH J . Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br J Clin Pharmacol. 1998; 46(2):111-6. PMC: 1873670. DOI: 10.1046/j.1365-2125.1998.00749.x. View

20.

Jonsson E, Karlsson M . Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58(1):51-64. DOI: 10.1016/s0169-2607(98)00067-4. View